CRDF

Rating neutralAI MemoPost-earnings T+3

Cardiff Oncology

As of 2026-08-04/Post-earnings T+3/Confidence low

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-04 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

low

Horizon

—

Key catalyst

Q2 earnings release and guidance check • 2026-08-04

Base target: $1 / p=50% prob

Biggest risk

The company remains a low-coverage, clinical-stage biotech with no verified post-July-30 earnings update, no confirmed analyst revision signal, and substantial clinical uncertainty. Financing and warrant dilution, a potential funding gap beyond the stated Q1 2027 runway, and a disclosed Nerviano license dispute add downside risk [#SEC-8K-2026-07-16] [#SEC-8K-2026-05-19].

Invalidation

Break below $0 or thesis failure.

What would change my mind?

The investment case rests on positive but early CRDF-004 efficacy, FDA-aligned Phase 3 planning, and potential confirmation in first-line RAS-mutated mCRC. The reported ORR differential and unreached median PFS could support rerating if reproduced in a registrational study [#PR-EARNINGS-2026-06-02] [#SEC-8K-2026-05-14].

Research note

Recommendation

neutral

Confidence

low

As of

2026-08-04

Base target

p=50%

Bull target

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Equity financing and warrant dilution
CRDF-004 confirmatory data and Phase 3 execution
The investment case rests on positive but early CRDF-004 efficacy, FDA-aligned Phase 3 planning, and potential confirmation in first-line RAS-mutated mCRC.

BearKey bullets

CRDF-004 remains an early, small-sample dose-finding study without confirmatory Phase 3 evidence.
Cardiff disclosed a license-agreement dispute with Nerviano concerning onvansertib [#SEC-8K-2026-05-19].
Phase 3 timing and regulatory-strategy details remain unconfirmed despite the company’s prior mid-2026 plan [#SEC-8K-2026-05-14].

WatchKey bullets

Q2 earnings release and guidance check

Summary

High-level snapshot

Recommendation

neutral

Model confidence

low

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $1 (p=50%)

Target spread vs base: +165% / -53%

Scenario probabilities

Bull Target: $2 (p=20%)Base Target: $1 (p=50%)Bear Target: $0 (p=30%)

Commentary

News tone is modestly constructive from the CRDF-004 data and FDA-aligned Phase 3 path, but financing dilution and unresolved clinical, regulatory, and licensing risks offset that signal. The scheduled T+3 earnings follow-up remains unverified; revenue/EPS surprise, guidance, analyst revisions, transcript commentary, and attributable post-print market reaction are unavailable. Social coverage is absent, and the loose peer set limits confidence.

As of 2026-08-04 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Equity financing and warrant dilution
CRDF-004 confirmatory data and Phase 3 execution

Scenarios

Bull Target (Scenario probability)

$2 / p=20% prob

Base Target (Scenario probability)

$1 / p=50% prob

Bear Target (Scenario probability)

$0 / p=30% prob

Analysis 2026-08-04 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.10

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-04
Q2 earnings release and guidance check
The scheduled 2026-07-30 T+3 earnings follow-up could not be confirmed: no verified Q2 release, 8-K exhibit, transcript, consensus surprise, guidance revision, analyst target change, or earnings-linked price explanation was available in the packet or bounded primary-source check. The latest verified earnings update reported $46.1 million of cash and investments and runway into Q1 2027 [#SEC-8K-2026-05-14]. This is an evidence gap, not a positive catalyst.
Prob 15.00% • Move 0.00% • Priced-in 80.00%
EVENT2026-11-02
Phase 3 design and regulatory-strategy update
Cardiff reported completion of an End-of-Phase 2 FDA meeting, selection of 30 mg onvansertib with FOLFIRI/bevacizumab for Phase 3, and plans to share additional Phase 3 and regulatory details in mid-2026. Subsequent confirmation was not found, reducing confidence [#SEC-8K-2026-05-14].
Prob 40.00% • Move 20.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

Equity financing and warrant dilution
2026-11-02
The July financing included 8.57 million common shares and accompanying warrants, with additional insider shares and warrants. The common warrants carry future exercise potential, creating dilution and supply overhang near a sub-$1 share price [#SEC-8K-2026-07-16].
Prob 75% • Move -12% • Priced-in 70%

Long-term Catalysts

Months to a year

CRDF-004 confirmatory data and Phase 3 execution
2027-08-04
The selected 30 mg arm reported confirmed ORR of 72.2% versus 42.1% for standard of care, while median PFS was not reached. Successful Phase 3 execution and confirmation could materially improve valuation, but the data remain early and no Phase 3 initiation date is confirmed [#PR-EARNINGS-2026-06-02].
Prob 30% • Move 60% • Priced-in 20%

Risks

CRDF-004 remains an early, small-sample dose-finding study without confirmatory Phase 3 evidence.
Cardiff disclosed a license-agreement dispute with Nerviano concerning onvansertib [#SEC-8K-2026-05-19].
Phase 3 timing and regulatory-strategy details remain unconfirmed despite the company’s prior mid-2026 plan [#SEC-8K-2026-05-14].
Q2 cash, burn, runway, guidance, and earnings-surprise data could not be verified as of 2026-08-04.
The July financing and warrants create material dilution and potential trading overhang [#SEC-8K-2026-07-16].

Peers

Symbol	Summary
ANVS	Same-sector market-cap comparator only; direct overlap with Cardiff’s RAS-mutated mCRC indication, onvansertib mechanism, or development stage is not validated.
GANX	Broad micro-cap biotechnology comparator; clinical, indication, and platform comparability are not established.
IBIO	Same-sector market-cap screening comparator only; not suitable for relative valuation without confirmed clinical or platform overlap.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-04

Loading AI feed…

Symbol

Summary

ANVS

Same-sector market-cap comparator only; direct overlap with Cardiff’s RAS-mutated mCRC indication, onvansertib mechanism, or development stage is not validated.

GANX

Broad micro-cap biotechnology comparator; clinical, indication, and platform comparability are not established.

IBIO

Same-sector market-cap screening comparator only; not suitable for relative valuation without confirmed clinical or platform overlap.